Treatment of osteoporosis in men with bisphosphonates: Rationale and latest evidence

Therapeutic Advances in Musculoskeletal Disease

Volumn 5, Issue 5, 2013, Pages 259-267

  Sim, Ie Wen ^a   Ebeling, Peter R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

alendronate; bisphosphonates; hypogonadism; osteoporosis; risedronate; zoledronic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; TESTOSTERONE; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY HEIGHT; BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; DRUG EFFICACY; FEVER; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; LUMBAR SPINE; MONOTHERAPY; MORBIDITY; MORTALITY; MYALGIA; OSSIFICATION; OSTEOCLAST; OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; SPINE FRACTURE;

EID: 84887482472     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X13500861     Document Type: Article

References (58)

1. Abbasi A. Rudman D. Wilson C. Drinka P. Basu S. Mattson D. et al (1995) Observations on nursing home residents with a history of hip fracture. Am J Med Sci 310: 229–234.
2. Benito M. Vasilic B. Wehrli F. Bunker B. Wald M. Gomberg B. et al (2005) Effect of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Miner Res 20: 1785–1791.
3. Bilezikian J. (2006) Osteonecrosis of the jaw – do bisphosphonates pose a risk? N Engl J Med 355: 2278–2281.
4. Boonen S. Orwoll E. Wenderoth D. Stoner K. Eusebio R. Delmas P. (2009) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24: 719–725.
5. Boonen S. Reginster J. Kaufman J. Lippuner K. Zanchetta J. Langdahl B. et al (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367: 1714–1723.
6. Borgstrom F. Johnell O. Jonsson B. Zethraeus N. Sen S. (2004) Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34: 1064–1071.
7. Chang K. Center J. Nguyen T. Eisman J. (2004) Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 19: 532–536.
8. Cooper C. Atkinson E. O'Fallon W. Melton L. 3rd (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 7: 221–227.
9. Dillon E. Urban R. Angel J. Casperson S. Paddon-Jones D. Sheffield-Moore M. (2008) Continuous testosterone administration for 5 months reduces markers of bone turnover in older men. FASEB J 22: 1188.
10. Ebeling P. (1998) Osteoporosis in men. New insights into aetiology, pathogenesis, prevention and management. Drugs Aging 13: 421–434.
11. Ebeling P.R. (2012) Clinical practice. Osteoporosis in men. New Engl J Med 358 (14): 1474–82.
12. Fink H. Ewing S. Ensrud K. Barrett-Connor E. Taylor B. Cauley J. et al (2006) Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 91: 3908–3915.
13. Finkelstein J. Hayes A. Hunzelman J. Wyland J. Lee H. Neer R. (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: 1216–1226.
14. Finkelstein J. Klibanski A. Neer R. Greenspan S. Rosenthal D. Crowley W. Jr (1987) Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 106: 354–361.
15. Greenspan S. Nelson J. Trump D. Resnick N. (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146: 416–424.
16. Grossmann M. Hamilton E. Gilfillan C. Bolton D. Joon D. Zajac J. (2011) Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust 194: 301–306.
17. Gullberg B. Johnell O. Kanis J. (1997) World-wide projections for hip fracture. Osteoporos Int 7: 407–413.
18. Ito K. Elkin E. Girotra M. Morris M. (2010) Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152: 621–629.
19. Jones G. Nguyen T. Sambrook P. Kelly P. Eisman J. (1994) Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ 309: 691–695.
20. Jones G. White C. Nguyen T. Sambrook P. Kelly P. Eisman J. (1996) Prevalent vertebral deformities: relationship to bone mineral density and spinal osteophytosis in elderly men and women. Osteoporos Int 6: 233–239.
21. Katznelson L. Finkelstein J. Schoenfeld D. Rosenthal D. Anderson E. Klibanski A. (1996) Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81: 4358–4365.
22. Kaufman J. Orwoll E. Goemaere S. San Martin J. Hossain A. Dalsky G. et al (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16: 510–516.
23. Khosla S. Lufkin E. Hodgson S. Fitzpatrick L. Melton L., 3rd (1994) Epidemiology and clinical features of osteoporosis in young individuals. Bone 15: 551–555.
24. Khosla S. Riggs B. Atkinson E. Oberg A. McDaniel L. Holets M. et al (2006) Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 21: 124–131.
25. Krabbe S. Hummer L. Christiansen C. (1984) Longitudinal study of calcium metabolism in male puberty. II. Relationship between mineralization and serum testosterone. Acta Paediatr Scand 73: 750–755.
26. Kurland E. Heller S. Diamond B. McMahon D. Cosman F. Bilezikian J. (2004) The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 15: 992–997.
27. Lespessailles E. (2013) Bisphosphonates and glucocorticoid-induced osteoporosis: efficacy and tolerability. Joint Bone Spine 80: 258–264.
28. Lyles K. Colon-Emeric C. Magaziner J. Adachi J. Pieper C. Mautalen C. et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799–1809.
29. Miller P. Delmas P. Lindsay R. Watts N. Luckey M. Adachi J. et al (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93: 3785–3793.
30. Mohr B. Guay A. O'Donnell A. McKinlay J. (2005) Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 62: 64–73.
31. Morishima A. Grumbach M. Simpson E. Fisher C. Qin K. (1995) Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80: 3689–3698.
32. Nguyen T. Eisman J. Kelly P. Sambrook P. (1996) Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol 144: 255–263.
33. Nordstrom P. Neovius M. Nordstrom A. (2007) Early and rapid bone mineral density loss of the proximal femur in men. J Clin Endocrinol Metab 92: 1902–1908.
34. O'Neill T. Felsenberg D. Varlow J. Cooper C. Kanis J. Silman A. (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11: 1010–1018.
35. Orwoll E. Binkley N. Lewiecki E. Gruntmanis U. Fries M. Dasic G. (2010 a) Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46: 970–976.
36. Orwoll E. Ettinger M. Weiss S. Miller P. Kendler D. Graham J. et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343: 604–610.
37. Orwoll E. Klein R. (1995) Osteoporosis in men. Endocr Rev 16: 87–116.
38. Orwoll E. Miller P. Adachi J. Brown J. Adler R. Kendler D. et al (2010 b) Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25: 2239–2250.
39. Orwoll E. Scheele W. Paul S. Adami S. Syversen U. Diez-Perez A. et al (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18: 9–17.
40. Pietschmann P. Kudlacek S. Grisar J. Spitzauer S. Woloszczuk W. Willvonseder R. et al (2001) Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest 31: 444–451.
41. Riggs B. Melton L. Robb R. Camp J. Atkinson E. McDaniel L. et al (2008) A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res 23: 205–214.
42. Ringe J. Faber H. Farahmand P. Dorst A. (2006) Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26: 427–431.
43. Rosen C. Bilezikian J. (2001) Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 86: 957–964.
44. Ross R. Small E. (2002) Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 167: 1952–1956.
45. Sawka A. Papaioannou A. Adachi J. Gafni A. Hanley D. Thabane L. (2005) Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 6: 39.
46. Seeman E. Bianchi G. Khosla S. Kanis J. Orwoll E. (2006) Bone fragility in men – where are we? Osteoporos Int 17: 1577–1583.
47. Shahinian V. Kuo Y. Freeman J. Goodwin J. (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352: 154–164.
48. Smith E. Boyd J. Frank G. Takahashi H. Cohen R. Specker B. et al (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331: 1056–1061.
49. Smith M. Eastham J. Gleason D. Shasha D. Tchekmedyian S. Zinner N. (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169: 2008–2012.
50. Smith M. Egerdie B. Hernandez Toriz N. Feldman R. Tammela T. Saad F. et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361: 745–755.
51. Smith M. McGovern F. Zietman A. Fallon M. Hayden D. Schoenfeld D. et al (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345: 948–955.
52. Stoch S. Parker R. Chen L. Bubley G. Ko Y. Vincelette A. et al (2001) Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86: 2787–2791.
53. Stoch S. Saag K. Greenwald M. Sebba A. Cohen S. Verbruggen N. et al (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36: 1705–1714.
54. Szulc P. Delmas P. (2001) Biochemical markers of bone turnover in men. Calcif Tissue Int 69: 229–234.
55. van der Werff ten Bosch J. Bot A. (1992) Some skeletal dimensions of males with isolated gonadotrophin deficiency. Neth J Med 41: 259–263.
56. Wang C. Swerdloff R. Iranmanesh A. Dobs A. Snyder P. Cunningham G. et al (2001) Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf) 54: 739–750.
57. Wells G. Cranney A. Peterson J. Boucher M. Shea B. Robinson V. et al (2008 a) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (1): CD004523.
58. Wells G. Cranney A. Peterson J. Boucher M. Shea B. Robinson V. et al (2008 b) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (1): CD001155.